Premier Alternatives

ImmuneBridge

San Francisco, CA · Founded 2018 · Privately Held (backing)

Developer of allogeneic cellular immunotherapies designed for advancing cancer treatment. ImmuneBridge is based in San Francisco, CA and was founded in 2018. Its last reported valuation was $25 million in Jan 2023. It has raised $19.7 million across 2 recorded rounds; the latest was a $5.6 million early-stage round in Mar 2025.

Last reported valuation
$25.0M
Oct 2026
Priced at
—
Total raised
$19.7M
Last round
Early Stage VC
Mar 2025

ImmuneBridge key facts

as of Oct 2026
  • Developer of allogeneic cellular immunotherapies designed for advancing cancer treatment.
  • ImmuneBridge is valued at approximately $25.0M as of Oct 2026 (last reported valuation).
  • It has raised $19.7M across 2 recorded rounds; the latest was Early Stage VC ($5.6M) in Mar 2025.
  • Notable investors include Pioneer Fund, Insight Partners (New York), Gaingels, Calm Ventures, Endless Frontier Labs — 16 tracked in total.
  • ImmuneBridge has filed 2 Form Ds with the SEC since 2023, most recently Apr 2025 ($5.6M sold to 6 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$25.0M

ImmuneBridge's last reported valuation, Jan 2023. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of ImmuneBridge with a free account
  • ·The complete investor list: 16 names
  • ·Watch ImmuneBridge: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

ImmuneBridge funding rounds

2 rounds
Mar 2025Early Stage VC$5.6MSEC filing▮
Dec 2022Early Stage VC$10.2MSEC filing▮
Full funding history →

ImmuneBridge valuation

ImmuneBridge's last reported valuation was $25 million in Jan 2023. No priced round, secondary trade or fund mark has surfaced since.

How much has ImmuneBridge raised?

ImmuneBridge has raised $19.7 million across 2 recorded rounds since 2022. The largest was a $5.6 million early-stage round in Mar 2025.

ImmuneBridge has filed 2 Form Ds with the SEC since 2023, most recently in Apr 2025 ($5.6 million sold to 6 investors).

ImmuneBridge investors

16 investors are on record for ImmuneBridge, including Pioneer Fund, Insight Partners (New York), Gaingels and Calm Ventures. By type, the record holds 7 venture capital firms and 1 private equity firm. The early-stage round in Mar 2025 drew 6 investors.

About ImmuneBridge

Developer of allogeneic cellular immunotherapies designed for advancing cancer treatment. The company's immunotherapies utilize proprietary expansion technology to amplify cord blood-derived immune stem cells while maintaining immune multipotency, offering a diverse and consistent cellular source, enabling progenitors with cellular pharmacopeia, and dealing with oncology treatments.

Sector
Healthcare
HQ
San Francisco, CA, United States
Founded
2018
Employees
16
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.